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Abstract: BACKGROUND Current guidelines consider vitamin K antagonists (VKA) the oral anticoagu-
lant agents of choice in adults with atrial arrhythmias (AA) and moderate or complex forms of congenital
heart disease, significant valvular lesions, or bioprosthetic valves, pending safety data on non-VKA oral
anticoagulants (NOACs). Therefore, the international NOTE registry was initiated to assess safety,
change in adherence and quality of life (QoL) associated with NOACs in adults with congenital heart
disease (ACHD). METHODS An international multicenter prospective study of NOACs in ACHD was
established. Follow-up occurred at 6 months and yearly thereafter. Primary endpoints were thromboem-
bolism and major bleeding. Secondary endpoints included minor bleeding, change in therapy adherence
(฀80% medication refill rate, ฀6 out of 8 on Morisky-8 questionnaire) and QoL (SF-36 questionnaire).
RESULTS In total, 530 ACHD patients (mean age 47 SD 15 years; 55% male) with predominantly
moderate or complex defects (85%), significant valvular lesions (46%) and/or bioprosthetic valves (11%)
using NOACs (rivaroxaban 43%; apixaban 39%; dabigatran 12%; edoxaban 7%) were enrolled. The most
common indication was AA (91%). Over a median follow-up of 1.0 [IQR 0.0-2.0] year, thromboembolic
event rate was 1.0% [95%CI 0.4-2.0] (n = 6) per year, with 1.1% [95%CI 0.5-2.2] (n = 7) annualized
rate of major bleeding and 6.3% [95%CI 4.5-8.5] (n = 37) annualized rate of minor bleeding. Adherence
was sufficient during 2 years follow-up in 80-93% of patients. At 1-year follow-up, among the subset of
previous VKA-users who completed the survey (n = 33), QoL improved in 6 out of 8 domains (p ฀ 0.05).
CONCLUSIONS Initial results from our worldwide prospective study suggest that NOACs are safe and
may be effective for thromboembolic prevention in adults with heterogeneous forms of congenital heart
disease.
DOI: https://doi.org/10.1016/j.ijcard.2019.06.014
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Background: Current guidelines consider vitamin K antagonists (VKA) the oral anticoagulant agents of choice in
adults with atrial arrhythmias (AA) and moderate or complex forms of congenital heart disease, significant val-
vular lesions, or bioprosthetic valves, pending safety data on non-VKA oral anticoagulants (NOACs). Therefore,
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the international NOTE registry was initiated to assess safety, change in adherence and quality of life (QoL) asso-
ciated with NOACs in adults with congenital heart disease (ACHD).
Methods: An international multicenter prospective study of NOACs in ACHDwas established. Follow-up occurred
at 6 months and yearly thereafter. Primary endpoints were thromboembolism and major bleeding. Secondary
endpoints included minor bleeding, change in therapy adherence (≥80% medication refill rate, ≥6 out of 8 on
Morisky-8 questionnaire) and QoL (SF-36 questionnaire).
Results: In total, 530 ACHD patients (mean age 47 SD 15 years; 55%male) with predominantlymoderate or com-
plex defects (85%), significant valvular lesions (46%) and/or bioprosthetic valves (11%) using NOACs
(rivaroxaban 43%; apixaban 39%; dabigatran 12%; edoxaban 7%) were enrolled. The most common indication
was AA (91%). Over a median follow-up of 1.0 [IQR 0.0–2.0] year, thromboembolic event rate was 1.0% [95%CI
0.4–2.0] (n = 6) per year, with 1.1% [95%CI 0.5–2.2] (n = 7) annualized rate of major bleeding and 6.3% [95%
CI 4.5–8.5] (n = 37) annualized rate of minor bleeding. Adherence was sufficient during 2 years follow-up in
80–93% of patients. At 1-year follow-up, among the subset of previous VKA-users who completed the survey
(n = 33), QoL improved in 6 out of 8 domains (p ≪ 0.05).
Conclusions: Initial results from our worldwide prospective study suggest that NOACs are safe and may be effec-
tive for thromboembolic prevention in adults with heterogeneous forms of congenital heart disease.
This is an open access article under the CC BY-NC-ND license. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Despite improved survival, adults with congenital heart disease
(ACHD) are at risk for thromboembolic complications including signifi-
cantly increased stroke rates compared to age- and sex-matched con-
trols [1–3]. The causes for this increased risk of stroke are
multifactorial, including high incidence rates of atrial arrhythmias, re-
sidual valvular heart disease, residual intracardiac shunts, presence of
cyanosis, myocardial scarring and ventricular dysfunction, and use of
prosthetic materials for intracardiac repair [4–6]. Consequently, appro-
priate use of oral antithrombotic drugs to prevent thromboembolism
is of paramount importance in this vulnerable patient group.
In Ruff meta-analysis, non-vitamin K antagonist oral anticoagulants
(NOACs) had a favourable risk–benefit profile in patients with non-
valvular atrial fibrillation,with significant reductions in stroke, intracra-
nial haemorrhage, andmortality, andwith similarmajor bleeding as for
vitamin K antagonists (VKA), but increased gastro-intestinal bleeding
[7]. Furthermore, NOACs offer an attractive alternatives to VKAs in the
young and active ACHD population in whom regular monitoring of the
international normalized ratio, dose adjustments, and dietary consis-
tency could adversely impact quality of life and adherence.
However, it is uncertain whether results from other populations are
applicable in ACHD patients considering the differences in structural
heart disease and pathophysiology for thromboembolic complications
[5]. To date, clinical data on the rates of thromboembolism and major
bleeding associatedwithNOACs in ACHDhas been scarce, and the avail-
able studies are hampered by limited sample sizes and short follow-up
periods [8–10]. Therefore, in the absence of large-scale data specific to
patients with congenital heart disease, current guidelines for ACHD pa-
tients caution against generalizing the results of NOAC trials to the
ACHD population beyond those with simple lesions (without
bioprosthetic valves or significant valve disease), atrial arrhythmias,
and a CHA₂DS₂-VASc score ≥ 2 [11].
In order to address a major knowledge gap regarding the safety and
efficacy of NOACs in the ACHD population, we initiated the worldwide
prospective NOTE registry (non-vitamin K antagonist oral anticoagu-
lants for thromboembolic prevention in patients with congenital heart
disease registry; ClinicalTrials.gov registration NCT02928133) through
the International Society for Adult Congenital Heart Disease (ISACHD).
2. Methods
2.1. Study design and participants
Initiated in April 2014, the NOTE registry is an open international prospective obser-
vational study with longitudinal follow-up in ACHD patients prescribed NOACs for
thromboprophylaxis. Any ACHD patient using NOACs (with an indication to continue for
at least 3months)was includedwith the exception of patientswithmechanical prosthetic
valves or significant mitral stenosis.
2.2. Medical ethics committee and informed consent
The NOTE registry protocol conforms to the ethical guidelines of the 1975 Declaration
of Helsinki as reflected in a priori approval by the institution's human research committee
of all participating medical centres. All individual participants provided informed consent
in accordancewith national and local regulations. Through collaboration ISACHD, patients
were recruited from 35 centres in 13 countries (Belgium, Canada, France, Israel, Italy,
Japan, Lithuania, Netherlands, Poland, Sweden, Switzerland, United Kingdom, United
States of America).
2.3. Inclusion and follow-up
Patients were identified at the participating institutions during clinical counter or by
means of national registries. The severity of their cardiac defect was classified according
to the classification (simple, moderate or complex) outlined by Task Force 1 of the 23rd
Bethesda Conference [12]. The choice of NOAC agent was at the discretion of the treating
cardiologist with no protocol-specific recommendation. The inception of the cohort was
triggered by prescription of NOACs or the time of first visit or telephone call if the patients
were already on NOACs. At inclusion, demographics, pre-defined clinical data including
history of anti-thromboticmedication use, history of thromboembolism and bleeding, fac-
tors associated with thromboembolism or bleeding, and details on prescription of NOACs
were collected. Prior use of VKAs was noted (VKA group), with data collected regarding
transitioning to NOAC. Those who did not transition from VKA to NOAC were defined as
a VKA-naive group. Significant valvular abnormalitieswere defined as any valvular disease
classified as moderate or severe. The first follow-up was at 6 months or 1 year and yearly
thereafter, coinciding with routine outpatient clinical visits or telephone contacts. At each
follow-up, data on the pre-defined end points were conducted and adjudicated by a
trained investigator or a site coordinator.
2.4. Data management
We collected patient data in an electronic case report form (eCRF) submitted through
a securewebsite,which is certified for GoodClinical Practice.We assigned all patientswith
a unique study identifier so that personal identifiable data could be removed at the hospi-
tal source, ensuring anonymity and protecting confidentiality. The principle registry coor-
dinator and each site coordinator examined the completeness and accuracy of the eCRFs.
The principle registry coordinator as an author had full access to all the data in the study
and takes responsibility for its integrity and the data analysis.
2.5. Endpoints
The primary efficacy endpoints were thromboembolism (ischemic cerebrovascular
accident; iCVA, transient ischemic attack; TIA, systemic or pulmonary embolism or intra-
cardiac thrombus formation). The primary safety endpoint was major bleeding (signifi-
cant bleeding necessitating hospitalization/interventions/≥2 units of packed red blood
cells, and/orwith a haemoglobin drop≫ 1.24mmol/L and/or bleeding thatwas fatal or oc-
curred in the following critical sites: intra-cranial, intra-spinal, intra-ocular, pericardial,
intra-articular, intra-muscular with compartment syndrome) according to the criteria
from the International Society on Thrombosis and Haemostasis [13].
Secondary endpoints included minor bleeding events (any bleeding not classified as
major bleeding), side-effects, therapy persistence, therapy adherence, quality of life
(QoL), and all-cause mortality. Therapy adherence was assessed yearly during follow-up,
using a questionnaire (Morisky 8) and interrogation from pharmacists regarding the
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quantity ofmedication collected by the patient during a defined time frame. In accordance
with the Morisky 8 questionnaire criteria, sufficient adherencewas defined as a score of 6
or higher (range 1 to 8; 8 corresponding to the highest adherence). Using the pharmacy
interrogation data, medication refill adherence (MRA) was calculated by dividing the
total days for which NOACs were supplied by the number of days of study participation.
This value was multiplied by 100 to obtain a percentage adherence rate [14]. We defined
sufficient adherence as ≥80%. QoL in patients was assessed yearly during follow-up by
means of the SF-36 questionnaire, with a focus on general functioning in daily life.
2.6. Sample size calculation
To estimate non-inferiority of NOACs compared with VKAs, we performed a sample
size estimate based on previously published event rates in ACHD patients with atrial ar-
rhythmias on VKAs, along with the risk ratio associated with NOACs versus VKAs in the
general populationwith atrial arrhythmias [15–17]. The non-inferioritymargin for throm-
botic events and stroke or systemic embolismwas set at+1.5% per year (annual event rate
3.1%) and major bleeding at +2.0% per year (annual event rate 5.9%). The sample size es-
timationwas performedwith a power of 0.8 and a one-sided significance level of 0.05. As a
result, an estimated 400 patient yearswere required to assess thenon-inferiority of NOACs
compared to VKAs.
2.7. Statistical analysis
Descriptive statistics were used to summarize baseline characteristics. Kaplan-Meier
survival curves were created to determine event-free survival. For comparison between
the NOAC group and the VKA group with the Kaplan-Meier survival curves, we censored
thepatients at 4 years follow-up in theVKA group,whichwas themaximumfollow-up pe-
riod of the NOAC group. Incidence rates of the outcomeswere calculated using Poisson re-
gression. For time-to-event analyses, subjects who discontinued NOACs or were lost to
follow-up were censored at the time of last known NOACs use. In case of a change in
QoL or therapy adherence over time, differences were analysed by a Wilcoxon signed
rank test or a chi-square test. Results are presented as mean with standard deviation
(SD), median with interquartile range (IQR) and incidence rates with 95% confidence in-
tervals (95%CIs). A p-value below 0.05 was considered statistically significant. Analyses
were performed using R version 3.2.4 (R core team) and SPSS version 23 (IBM).
3. Results
3.1. Baseline characteristics
In total, 530 ACHD using NOACs (rivaroxaban 43%; apixaban 39%;
dabigatran 12%; edoxaban 7%) were recruited between April 2014 and
August 2018 (mean age 47 SD 15 years; 55% male, Table 1) from 13
countries distributed over Europe, North-America and Asia. The cohort
consisted of patients with heterogeneous forms of congenital heart dis-
ease classified as complex in 40%, moderate in 45%, and simple in 15%
(Fig. 1). At baseline, 56% of patients were not on any anti-thrombotic
therapy, 15% were on aspirin, 1% on NOACs, and 28% on VKA (14 with
concomitant aspirin use). The large majority of patients (91%, n =
481) started NOACs for thromboembolic prophylaxis in the context of
atrial arrhythmias (Appendix I). Other indications were primary (3%, n
= 17) and secondary (6%, n = 32) prevention of thromboembolism
in the absence of atrial arrhythmias. In all, 54% and 95% of patients
had CHA2DS2-VASc and HAS-BLED scores≪2, respectively (per indica-
tion, see Appendix I). Overall, 11% had a bioprosthetic valve(s) (aortic
valve n = 6, pulmonary valve n = 46, mitral valve n = 1, tricuspid
valve n=1, pulmonary and tricuspid valves n= 3), 46% had significant
valvular abnormalities (pulmonic regurgitation n = 48, pulmonic ste-
nosis n = 17, aortic regurgitation n = 43, aortic stenosis n = 7, mitral
regurgitation n= 114, tricuspid regurgitation n= 171, tricuspid steno-
sis n = 4), 8% had pulmonary hypertension and 31% had a history of
heart failure defined by clinical signs or low systolic systemic ventricular
function by imaging (Table 1). Seventy-four patients (14%) had a Fontan
circulation (atriopulmonary connection, n = 26; total cavopulmonary
connection, n = 48) with the following indications for NOACs: 69%
atrial arrhythmias, 16% primary and 15% secondary prevention of
thromboembolism.
3.2. Prescription pattern of NOACs
Reasons for selecting a specific agent and for prescribing a NOAC
over a VKA were reported by 262 physicians. Most physicians selected
NOACs instead of VKAs due to the absence of need for laboratory mon-
itoring of anticoagulation (45%). Other reasons for selection of NOACs
over VKA were labile international normalized ratio (INR) (7%), physi-
cian preference (6%), potentially reduced risk of intracranial bleeding
(3%), bleeding complication under VKA (2%), intolerance of VKA (1%)
and unknown (36%). Reasons for physicians to choose a specific type
of NOAC (n= 53) were once daily regimen (22%), physician preference
(19%), reported lowest bleeding risk (15%), gastro-intestinal symptoms
(13%) and side-effects with other NOAC (11%).
3.3. Primary endpoints in NOAC cohort
The total duration of follow-upwas 613 patient-years with amedian
duration of 1.0 [IQR 0.0–2.0] year. During follow-up, 6 patients (1.1%)
experienced thromboembolic events (pulmonary embolism n = 2; in-
tracardiac thrombus n = 2; deep vein thrombosis n = 1; ischemic
stroke n= 1) and 7 patients (1.3%) hadmajor bleeding events (menor-
rhagia n = 4; gastro-intestinal bleeding n = 2; hematuria n = 1) (Fig.
2a). The rate of thromboembolic events (n = 6) was 1.0% [95%CI 0.4–
2.0] per year. The rate of major bleeding (n = 7) was 1.1% [95%CI 0.5–
2.2] per year. None of these events was related to interventional or sur-
gical procedures and all were observed in patients with moderate to
complex defects (Table 2). Out of 6 patients with thromboembolic
events, 4 patients switched to VKA and 2 remained on the same
NOACs. In 7 patients with major bleeding, 5 patients were switched to
VKA, 1 switched to another NOAC and 1 remained on the same NOAC.
In total, 37 patients experiencedminor bleeds translating into an annual
rate of 6.3% [95%CI 4.5–8.5] per year (Appendix II). A total of 57 patients
Table 1
Baseline characteristics of ACHD patients using NOACs.
All (n = 530) Previous VKA (n = 150)
Age at inclusion, y 47 SD15 47 SD16
Male, n (%) 289 (55) 74 (49)
Severity of congenital heart defect, n (%)
Simple 79 (15) 22 (15)
Moderate 239 (45) 58 (39)
Complex 212 (40) 70 (47)
Defect repaired, n (%) 421 (79) 125 (87)
Fontan circulation, n (%) 74 (14) 37 (25)
Bioprosthetic valves, n (%) 57 (11) 14 (9)
Significant valvular lesion, n (%) 243 (46) 65 (43)
Median CHA2DS2-VASc 1 [1–3] 2 [1–3]
Cardiovascular history, n (%)
Stroke or TIA 54 (10) 17 (11)
Pulmonary embolism 22 (4) 10 (7)
Deep venous thrombosis 9 (2) 2 (1)
Intracardiac thrombus 11 (2) 4 (3)
Systemic embolism 9 (2) 3 (2)
Myocardial infarction 2 (0.5) 1 (1)
Other type of thrombus 4 (1) 2 (1)
Heart failure⁎ 163 (31) 63 (42)
Hypertension 121 (23) 36 (24)
Diabetes mellitus 49 (9) 14 (9)
Median HASBLED 0 [0–1] 0 [0–1]
History of major bleeding, n (%) 17 (3) 11 (7)
Values are presented asmean (standard deviation, SD), median (interquartile range, IQR)
or counts (%).
Abbreviations: VKA, vitamin K antagonist; CHA2DS2-VASc, stroke risk factor scoring sys-
tem in which 1 point is given for heart failure, hypertension, age 64–74 years, diabetes
mellitus, history of vascular disease, female sex and 2 points are given for age ≥ 75 years,
history of stroke/TIA/thromboembolism; HASBLED, bleeding risk factor scoring system
in which 1 point is given for uncontrolled hypertension, abnormal renal or liver function,
history of stroke or bleeding, labile international normalized ratio, age ≫ 65 years, use of
nonsteroidal anti-inflammatory drugor antiplatelet agents or alcohol; TIA, transient ische-
mic attack; ASA, aspirin or ascal.
⁎ Heart failure is defined as the presence of signs and symptoms of either right (ele-
vated central venous pressure, hepatomegaly, dependent oedema) or left ventricular fail-
ure (exertional dyspnoea, cough, fatigue, orthopnoea, paroxysmal nocturnal dyspnoea,
cardiac enlargement, crackles, gallop rhythm, pulmonary venous congestion) or both, con-
firmed by non-invasive or invasive measurements demonstrating objective evidence of
cardiac dysfunction.
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(10.7%) permanently ceased NOACs during follow-up. Reasons for ces-
sation are illustrated in Appendix III.
3.4. Primary endpoints in historical VKA cohort
Among the 530 patients, 28% (n=150)were previously on VKA be-
fore starting the NOACs. These patients served as a historical control
group. Complication rates of these patients, while treated with VKA,
were analysed retrospectively. The mean follow-up time under treat-
ment with VKA was 3.8 [IQR 1.1–8.6] years. During the period under
VKA, 12 patients experienced thromboembolic events, accounting for
1.2% per year [95%CI 0.6–2.1] (Fig. 2b) and 9 hadmajor bleeding events,
accounting for 1.1% per year [95%CI 0.5–1.9]) (Fig. 2c).
3.5. Secondary endpoints in NOAC cohort
Using pharmacy interrogation data, adherence was sufficient (≥80%
of the pills received) at 1- and 2-year follow-up in 95% (n=41) and 93%
(n = 28) of patients, respectively. Based on the Morisky-8 question-
naire, adherence was sufficient (=score ≥ 5) in 80% (n = 69) and 91%
(n = 49) of patients at 1 and 2 years of follow-up, respectively. There
was no appreciable difference between 1- and 2-year follow-up rates
of adherence using pharmacy interrogation (p = 0.500) or Morisky-8
questionnaire (p = 0.453).
QoL questionnaire was completed by 72 patients at baseline and at
1 year follow-up (Appendix IV), 33 of whom had received a VKA prior
to the NOAC. In the VKA subgroup (n = 33), QoL was improved in 6
out of 8 domains (social functioning p = 0.027, mental health p =
0.003, role emotional p=0.027, vitality p=0.022) following transition
to a NOAC. In VKA-naïve group (n = 39), no domain of QoL declined
over 1 year.
4. Discussion
This is the largest prospective cohort study to assess the safety and
short-term efficacy of NOACs in ACHD. Our results show low rates of
thromboembolic complication (1.0% [95%CI 0.4–2.0] per year) and
major bleeding complications (1.1% [95%CI 0.5–2.2] per year). Compar-
isons to historical cohorts suggest that NOACs have non-inferior safety
and short-term efficacy profiles when compared to VKAs in ACHD pa-
tients. Furthermore, adherence to NOACs was stable and sufficient dur-
ing 2 years of follow-up and QoL at 1 year of follow-up improved in 6
out of 8 domains in patientswhopreviously used VKAs and transitioned
to NOACs.
Previously, two retrospective studies evaluated the rates of
thromboembolic- and major bleeding events in ACHD patients with
atrial arrhythmias on VKAs, antiplatelet therapy, or no
thromboprophylaxis [15,18]. Heidendael et al. followed 229 ACHD pa-
tients with atrial arrhythmias for a median follow-up of 6 years and re-
ported an annualized thromboembolic event rate of 1.4% in 191 patients
(using VKAs, antiplatelet therapy or both, along with an annualized
major bleeding rate of 4.4% in 164 VKA users [15]. Khairy et al. reported
an annualized thromboembolic event rate of 1.14% in 482 ACHD pa-
tients (38% antiplatelet therapy, 54% OAC including≫90% VKAs, 8% nei-
ther) and an annualized major bleeding rate of 0.77% in 262 VKA users
during a median follow-up of 5.9 years [18]. Direct comparisons to pa-
tients in the NOTE registry are obscured by the various
thromboprophylaxis treatment regimens, inclusion of patients with
contraindications to NOACs such as mechanical valves, and differing in-
dications for anticoagulation (e.g. limited to atrial arrhythmias in the
two cohort studies but not the NOTE registry). Nevertheless, the re-
ported thromboembolic and major bleeding rates of 1.1–1.3% and 0.8–
4.4% per year are similar to the rates observed with NOACs in the
NOTE registry. Furthermore, the results of this study are consistent
with a previous smaller study of 75 ACHD on NOACs that reported nei-
ther thromboembolic nor major bleeding event during 1 year of follow-
up [9]. In this cohort, only 16 (21%) had complex congenital heart dis-
ease, thereby preluding firm conclusions as to the merits of NOACs in
this patient population.
In the absence of data, the most recent 2018 AHA/ACC guideline for
the management of adults with congenital heart disease set a high-
impact research question as which patients with ACHD can use NOAC
instead of warfarin [19]. Furthermore, the 2014 PACES/HRS expert con-
sensus statement on the management of arrhythmias in ACHD issued a
weak recommendation (Class IIb, level of evidence C) stating that in
adults with simple forms of congenital heart disease and no prosthetic
heart valve or hemodynamically significant valve disease, a NOAC may
be a reasonable alternative to a VKA when anticoagulation is indicated.
Fig. 1.Congenital heart defect distribution of ACHDpatients using NOACs (n=530). Abbreviations: ToF—tetralogy of Fallot; TGA—transposition of great arteries; ASD—atrial septal defect;
PS—pulmonary stenosis; TA—tricuspid atresia; Anomalous PV drainage—anomalous pulmonary venous drainage; PA—pulmonary atresia; AVSD—atrioventricular septal defect; CoA—
coarctation of aorta; DORV—double outlet right ventricle; VSD—ventricle septal defect; Other—congenital defects with n ≪ 5 (tricuspid atresia, hypertrophic cardiomyopathy, Marfan
syndrome, congenitally corrected transposition of the great arteries, dextrocardia, atrial septum abnormality, mitral valvar abnormality, tricuspid valvar abnormality, cor triatriatum,
coronary sinus abnormality, double chambered right ventricle, double outlet left ventricle, double inlet left ventricle, Holt Oran syndrome, patent arterial duct, subaortic membrane,
truncus arteriosis, White-Bland-Garland syndrome).
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Fig. 2. a) Kaplan-Meier curves for survival free from thromboembolic event, major bleeding and minor bleeding under NOACs. b) Kaplan-Meier curves for survival free from
thromboembolic event according to use of NOACs and previous VKA use. c) Kaplan-Meier curves for survival free from major bleeding according to use of NOACs and previous VKA
use. Abbreviations: NOAC-non vitamin-K antagonist oral anticoagulant; VKA-vitamin K antagonist.
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The panel concluded that there was insufficient safety and efficacy data
to recommendNOACs in thosewithmoderate or complex forms of con-
genital heart disease [20]. Our study addresses this knowledge gap and
provides reassuring safety data in a cohort with predominantly moder-
ate and complex forms of congenital heart disease (85%), including a
Fontan circulation (14%). So far, only one study previously evaluated
the safety of NOACs in Fontan patients (n = 21) who are prone to
thrombus formation and bleeds [21,22], and reported 1 thromboem-
bolic event and no major bleeding event during a median follow-up of
13 months [10]. However, in our study, 50% of thromboembolic events
and major bleeds occurred in Fontan patients, each in 3 of 74 patients
(4.1%), confirming their vulnerability for these events. Fontan patients,
therefore, remain an important subgroup in whom further data are re-
quired to draw definitive conclusions regarding the safety of efficacy
of NOACs.
Our reassuring thromboembolic and major bleeding rates overall
may reflect, in part, the low median CHA2DS2-VASc and HAS-BLED
scores observed in this young cohort. Previous studies showed mixed
results regarding the applicability of CHA2DS2-VASc and HAS-BLED
scores in ACHD patients with atrial arrhythmias [15,18,23]. Although
patients with thromboembolic events in the NOTE registry seemed to
have low CHA2DS2-VASc scores and those with major bleeding events
had low HAS-BLED scores (Table 2), correlations could not be assessed
given the limited number of events. Furthermore, factors beyond
those included in the CHA2DS2-VASc score may be associated with
thromboembolic events in ACHD patients. For example, studies have
shown that, rather than traditional atherosclerotic risk factors, com-
plexity of congenital heart disease, heart failure, previous shunt opera-
tions, residual/unclosed septal defects and cyanosis (Eisenmenger
syndrome) were associated with thromboembolism in ACHD patients
[2,3,18,24,25].
In 2014, the PACES/HRS expert consensus statement did not recom-
mendprescribingNOACs to ACHDpatientswith prosthetic valves or he-
modynamically significant valve disease [20]. What constitutes
significant valve disease with contraindication to NOAC use was later
clarified in 2015 European and Canadian guidelines to includemechan-
ical prosthetic valves, any degree of rheumaticmitral stenosis, andmod-
erate or severe non-rheumatic mitral stenosis [26,27]. Although
controversial, NOAC use in patients with bioprosthetic valves is thought
to be reasonable, particularly for valves in the aortic position. Three
major studies (two meta-analyses and post-hoc analysis of randomised
controlled trial of edoxaban) have consistently shown that the overall
efficacy and safety of NOACswere not affected by the presence of valvu-
lar diseases (other than moderate/severe mitral stenosis or mechanical
heart valves) nor prior valve surgery (bioprosthesis replacement, valve
repair, valvuloplasty) in patients with atrial fibrillation [28–30]. In half
of the NOTE registry cohort, valve diseasewas prevalentwith 11% of pa-
tients having bioprosthetic valves (none of them usedNOACs for the in-
dication of bioprosthetic valves) but none having a mechanical valve or
mitral stenosis. Reassuringly, no thromboembolic event and only one
major bleed occurred in patients with bioprosthetic valves. Hence, we
conclude that when anticoagulation is indicated, it appears reasonable
to consider NOACs in ACHD patients with bioprosthetic valves or valvu-
lar heart disease, except mitral valve stenosis or mechanical valves.
Adherence to long-term anticoagulation is a concern that is ampli-
fied by the lack of blood testing monitoring for patients on NOACs. Al-
though there is no adherence data on VKA use in ACHD patients for
comparison, our data showed higher rates of NOAC adherence com-
pared with previous studies of NOAC adherence in the general popula-
tion (e.g. with pharmacy interrogation, 93–95% vs. 67–88% [31,32]).
This could be due to a greater awareness among ACHD patients regard-
ing their heart disease, more intense monitoring and education by
Table 2









1 30 ♂ Coronary AV
fistula
Deep vein thrombosis Dabigatran Atrial
arrhythmia
3 2 No TR
2 42 ♂ Fontan Pulmonary embolism Apixaban Atrial
arrhythmia
0 3 No No




2 1 No No
4 44 ♂ ToF Pulmonary embolism Apixaban Atrial
arrhythmia
1 1 No No
5 23 ♂ Fontan Ischemic stroke Apixaban Atrial
arrhythmia
1 0 No No














1 56 ♀ Fontan GI-bleeding Apixaban Atrial arrhythmia 2 1 No MR
2 71 ♀ PAPVC GI-bleeding Rivaroxaban Atrial arrhythmia 3 1 No TR
3 23 ♀ CoA Menorrhagia Rivaroxaban Atrial arrhythmia 2 0 Aortic &
pulmonary
No
4 42 ♀ Eisenmenger Menorrhagia Rivaroxaban Secondary prevention of pulmonary
embolism
3 2 No No
5 41 ♀ Fontan Menorrhagia Apixaban Atrial arrhythmia 4 0 No MR
6 80 ♂ ToF Hematuria Apixaban Atrial arrhythmia 4 1 No PS
7 67 ♀ Fontan Menorrhagia Rivaroxaban Atrial arrhythmia 2 2 No No
Abbreviations: CHD=congenital heart disease; TE= thromboembolism;NOAC=non-vitaminK antagonist oral anticoagulant; CHA2DS2-VASc, stroke risk factor scoring system inwhich
1 point is given for heart failure, hypertension, age 64–74 years, diabetes mellitus, history of vascular disease, female sex and 2 points are given for age ≥ 75 years, history of stroke/TIA/
thromboembolism; HASBLED, bleeding risk factor scoring system in which 1 point is given for uncontrolled hypertension, abnormal renal or liver function, history of stroke or bleeding,
labile international normalized ratio, age≫ 65 years, use of nonsteroidal anti-inflammatory drug or antiplatelet agents or alcohol; Coronary AV fistula = coronary arteriovenous fistula;
ToF= tetralogy of Fallot; TGA= transposition of great arteries; PAPVC= partial anomalous pulmonary venous connection; CoA= coarctation of the aorta; GI-bleeding = gastro-intes-
tinal bleeding; MR= mitral valve regurgitation; TR = tricuspid valve regurgitation; PS = pulmonary stenosis.
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physicians, and/or a Hawthorn effect due to participation in a registry
[33]. Interestingly, knowledge of oral anticoagulants appears to be sim-
ilar among ACHD patients and those with acquired heart disease and
thus does not seem to be a likely explanation [34]. Despite the
reassuring data, given the prospect of long term use of
thromboprophylaxis in these patients and the small number of partici-
pants, prescribers should always be aware of the risk of non-
persistence and adverse effects of therapy and evaluate these issues
on a regular basis. In patients, who used VKA at baseline, the overall
QoL improved after using NOACs for 1 year. These improvements
could be due to freedom from repeat monitoring and dose adjustments
based on food/drug interactions [35].
5. Limitations
This study is limited by the heterogeneity of the ACHD population,
low event rates and the observational design. Therefore, the data should
be interpreted with caution pending longer follow-up and validation in
other cohorts with a different mix of congenital defects and defect-
specific indications for anticoagulation. Furthermore, it should be
taken into consideration that unavoidably, some patients may have
been switched to a NOAC in order to be included in this registry. Al-
thoughwe analysed the historical data of VKAusers at baseline for com-
pleteness, these patients may not be representative of the typical VKA
users owing to the fact that the VKA was switched to a NOAC for a rea-
son that could have included a complication associated with VKA such
as bleeding or thromboembolic event. The small number of events pre-
cluded exploratory regression analyses to determine factors associated
with thromboembolic and bleeding events. Finally, results should not
be extrapolated to the distant future considering the relatively short
follow-up period (average follow-up 1 year). We expect to address
many of these limitations in the future with ongoing recruitment into
the global registry and longer-term follow-up. However, if feasible, a
head-to-head comparison of NOACs and VKAs by randomised con-
trolled trial in this group would be ideal to establish efficacy of NOACs.
In the largest study to date on NOAC use in ACHD patients across 13
countries, NOACs appeared to be safe and effective in the short term for
thromboprophylaxis in patients with predominantly moderate and
complex forms of congenital heart disease, including thosewith various
forms of valve disease and bioprosthetic valves. Future recommenda-
tions on anticoagulation in ACHD should consider this international ex-
perience. Larger studies with longer-term follow-up are required to
determine factors associatedwith thromboembolic and bleeding events
in NOAC users and to assess safety and efficacy in higher risk subgroups,
such as those with Fontan palliation.
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